Secondary Patenting of Branded Pharmaceuticals
October 10, 2012 | Journal Article
This article examines how secondary patents can extend market exclusivity and thus delay generic competition.
Prescription Drugs and Services
You are now viewing 1 - 10 of 17 results
Sort results by:
The Food and Drug Administration Has The Legal Basis to Restrict Promotion of Flawed Comparative Effectiveness Research
October 8, 2012 | Journal Article
Under FDA policy, communications by prescription drug manufacturers must be backed by “substantial evidence” from “adequate and well-controlled investigations.” But numerous exceptions permit manufacturer promotion based on data other than randomized trials.
Ethical Considerations in Orphan Drug Approval and Use
August 1, 2012 | Journal Article
While the 1983 Orphan Drug Act led to a boom in development and production of orphan drugs, inattentive regulatory standards may imperil patients with rare diseases.
Nurse Identified Hospital to Home Medication Discrepancies
May 1, 2010 | Journal Article
In this study, nurse interventionists identified and documented medication discrepancies from two Inland Northwest hospitals. The researchers identified more system-level discrepancies than patient-level ones.
Change in Rx Label Design Has No Effect on Patient Medication Use, Safety or Health
September 30, 2009 | Program Result Report
Brigham and Women's Hospital in Boston conducted a study to see if an improved label design for prescription drugs influenced patients' adherence to essential medications, safety and health outcomes for specific chronic diseases.
Can Improved Prescription Medication Labeling Influence Adherence to Chronic Medications?
May 1, 2009 | Journal Article
The introduction of a more readable prescription medication label by a pharmacy chain had little effect on medication adherence among chronically-ill patients.
Drug-Review Deadlines and Safety Problems
March 27, 2008 | Journal Article
This article considers the effects of the deadlines imposed on the Food and Drug Administration by the Prescription Drug User Fee Act. The Act was intended to expedite the review process, but according to these findings may have compromised safety.
Is Having More Preapproval Data the Best Way to Assure Drug Safety?
September 1, 2008 | Commentary
An intensified focus on drug safety often leads to demands for more data collection prior to drug approval. Increased post-marketing surveillance can also play an important role, but the optimal approach must be chosen for each case as it arises.
Computerized Prescription Ordering Can Help Hospitals Prevent Medication Errors
March 1, 2003 | Program Result Report
The Leapfrog Group developed standards for evaluating hospitals' use of computerized physician order entry systems, and devised and tested techniques to raise awareness about the importance of considering the presence of systems.
Nurses' Practice Environments, Error Interception Practices, and Impatient Medication Errors
June 1, 2012 | Journal Article
Nurses play a critical role in identifying and intercepting medication errors regardless where the error originates—at the prescribing, transcribing, dispensing or administration stages.